NF-kB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors
AuthorsMcCarthy, Brian A.
MetadataShow full item record
AbstractBackground: Abnormal NF-κB2 activation has been implicated in the pathogenesis of multiple myeloma, a cancer of plasma cells. However, a causal role for aberrant NF-κB2 signaling in the development of plasma cell tumors has not been established. Also unclear is the molecular mechanism that drives the tumorigenic process. We investigated these questions by using a transgenic mouse model with lymphocyte-targeted expression of p80HT, a lymphoma-associated NF-κB2 mutant, and human multiple myeloma cell lines.
Methods: We conducted a detailed histopathological characterization of lymphomas developed in p80HT transgenic mice and microarray gene expression profiling of p80HT B cells with the goal of identifying genes that drive plasma cell tumor development. We further verified the significance of our findings in human multiple myeloma cell lines.
Results: Approximately 40% of p80HT mice showed elevated levels of monoclonal immunoglobulin (M-protein) in the serum and developed plasma cell tumors. Some of these mice displayed key features of human multiple myeloma with accumulation of plasma cells in the bone marrow, osteolytic bone lesions and/or diffuse osteoporosis. Gene expression profiling of B cells from M-protein-positive p80HT mice revealed aberrant expression of genes known to be important in the pathogenesis of multiple myeloma, including cyclin D1, cyclin D2, Blimp1, survivin, IL-10 and IL-15. In vitro assays demonstrated a critical role of Stat3, a key downstream component of IL-10 signaling, in the survival of human multiple myeloma cells.
Conclusions: These findings provide a mouse model for human multiple myeloma with aberrant NF-ÎºB2 activation and suggest a molecular mechanism for NF-ÎºB2 signaling in the pathogenesis of plasma cell tumors by coordinated regulation of plasma cell generation, proliferation and survival.
CitationBMC Cancer. 2012 May 29; 12:203
- NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis.
- Authors: Zhang B, Wang Z, Li T, Tsitsikov EN, Ding HF
- Issue date: 2007 Jul 15
- Constitutive production of NF-kappaB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression.
- Authors: Wang Z, Zhang B, Yang L, Ding J, Ding HF
- Issue date: 2008 Apr 18
- NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation.
- Authors: Nadiminty N, Chun JY, Lou W, Lin X, Gao AC
- Issue date: 2008 Dec 1
- A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.
- Authors: Boylan KL, Gosse MA, Staggs SE, Janz S, Grindle S, Kansas GS, Van Ness BG
- Issue date: 2007 May 1
- NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.
- Authors: Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC
- Issue date: 2013 Aug